ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, vol.84, no.10, pp.987-991, 2005 (SCI-Expanded)
Background. Markers of fibrinolysis, thrombin-activatable fibrinolysis inhibitor (TAFI), tissue-type plasminogen activator (tPA), and plasminogen activator inhibitor-1 (PAI-1) levels were studied for the evaluation of short-term effects of raloxifene administration in postmenopausal women.